Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program
Circulation · 2024
DOI: 10.1161/circulationaha.123.066941 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2024. Verfasst von Michel Azizi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, France (M.A.). Hauptthemen laut MEDLINE: Hypertension, Renal Artery. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: ReCor Medical.
Abstract (Originalsprache)
BACKGROUND: The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, RADIANCE-HTN TRIO, and RADIANCE II (A Study of the Recor Medical Paradise System in Stage II Hypertension) trials independently met their primary end point of a greater reduction in daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. To characterize the longer-term effectiveness and safety of uRDN versus sham at 6 months, after the blinded addition of antihypertensive treatments (AHTs), we pooled individual patient data across these 3 similarly designed trials. METHODS: Patients with mild to moderate hypertension who were not on AHT or with hypertension resistant to a standardized combination triple AHT were randomized to uRDN (n=293) versus sham (n=213); they were to remain off of added AHT throughout 2 months of follow-up unless specified blood pressure (BP) criteria were exceeded. In each trial, if monthly home BP was ≥135/85 mm Hg from 2 to 5 months, standardized AHT was sequentially added to target home BP
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, France (M.A.).
- AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE, Paris, France (M.A.).
- INSERM, Paris, France (M.A.).
- University Hospital of Wales and Cardiff University, Cardiff, UK (A.S.P.S.).
- The Brigham and Women's Hospital, Boston, MA (N.D.L.F.).
- Division of Cardiovascular Medicine, State University of New York, Downstate Medical Center, New York (M.A.W., M.S.).
ORCID-Profile: Michel Azizi, Andrew S P Sharp, Naomi D L Fisher, Michael A Weber, Melvin D Lobo, Joost Daemen, Philipp Lurz, Felix Mahfoud, Roland E Schmieder, Jan Basile, Manish Saxena, Kintur Sanghvi, J Stephen Jenkins, Chandan Devireddy, Florian Rader, Lisa Claude, Ajay J Kirtane
Förderung
- ReCor Medical
Zitieren
APA
Azizi, M., Sharp, A. S. P., Fisher, N. D. L., Weber, M. A., Lobo, M. D., Daemen, J., Lurz, P., Mahfoud, F., Schmieder, R. E., Basile, J., Bloch, M. J., Saxena, M., Wang, Y., Sanghvi, K., Jenkins, J. S., Devireddy, C., Rader, F., Gosse, P., Claude, L., …, & RADIANCE Investigators (2024). Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. Circulation. https://doi.org/10.1161/circulationaha.123.066941
Vancouver
Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, et al. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. Circulation. 2024. doi:10.1161/circulationaha.123.066941
BibTeX
@article{Azizi2024,
author = {Azizi, Michel and Sharp, Andrew S P and Fisher, Naomi D L and Weber, Michael A and Lobo, Melvin D and Daemen, Joost and Lurz, Philipp and Mahfoud, Felix and Schmieder, Roland E and Basile, Jan and Bloch, Michael J and Saxena, Manish and Wang, Yale and Sanghvi, Kintur and Jenkins, J Stephen and Devireddy, Chandan and Rader, Florian and Gosse, Philippe and Claude, Lisa and Augustin, Dimitri A and McClure, Candace K and Kirtane, Ajay J and RADIANCE Investigators, RADIANCE Investigators},
title = {Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program},
journal = {Circulation},
year = {2024},
doi = {10.1161/circulationaha.123.066941}
}
EUVIMED